Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective, Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Have Acute Major Bleeding (ANNEXA-4)
2015-001785-26Phase 3Completed
- Sponsor
- Portola Pharmaceuticals
- Start
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of andexanet alfa in Acute major hemorrhage, sponsored by Portola Pharmaceuticals. Started Aug 2015; status: completed.
02
Drugs
andexanet alfa
03
Conditions
Acute major hemorrhage
Beyond the preview
Go deeper on 2015-001785-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001785-26.